Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Monocytes and interstitial macrophages contribute to hypoxic pulmonary hypertension
Rahul Kumar, … , Qadar Pasha, Brian B. Graham
Rahul Kumar, … , Qadar Pasha, Brian B. Graham
Published January 30, 2025
Citation Information: J Clin Invest. 2025;135(6):e176865. https://doi.org/10.1172/JCI176865.
View: Text | PDF
Research Article Inflammation Vascular biology

Monocytes and interstitial macrophages contribute to hypoxic pulmonary hypertension

  • Text
  • PDF
Abstract

Hypoxia is a major cause of pulmonary hypertension (PH) worldwide, and it is likely that interstitial pulmonary macrophages contribute to this vascular pathology. We observed in hypoxia-exposed mice an increase in resident interstitial macrophages, which expanded through proliferation and expressed the monocyte recruitment ligand CCL2. We also observed an increase in CCR2+ macrophages through recruitment, which express the protein thrombospondin-1, which functionally activates TGF-β to cause vascular disease. Blockade of monocyte recruitment with either CCL2-neutralizing antibody treatment or CCR2 deficiency in the bone marrow compartment suppressed hypoxic PH. These data were supported by analysis of plasma samples from humans who traveled from low (225 m) to high (3500 m) elevation, revealing an increase in thrombospondin-1 and TGF-β expression following ascent, which was blocked by dexamethasone prophylaxis. In the hypoxic mouse model, dexamethasone prophylaxis recapitulated these findings by mechanistically suppressing CCL2 expression and CCR2+ monocyte recruitment. These data suggest a pathologic cross talk between 2 discrete interstitial macrophage populations, which can be therapeutically targeted.

Authors

Rahul Kumar, Kevin Nolan, Biruk Kassa, Neha Chanana, Tsering Palmo, Kavita Sharma, Kanika Singh, Claudia Mickael, Dara Fonseca Balladares, Julia Nilsson, Amit Prabhakar, Aastha Mishra, Michael H. Lee, Linda Sanders, Sushil Kumar, Ari B. Molofsky, Kurt R. Stenmark, Dean Sheppard, Rubin M. Tuder, Mohit D. Gupta, Tashi Thinlas, Qadar Pasha, Brian B. Graham

×

Figure 6

DEX prophylaxis in humans to travel to high elevation suppresses inflammatory proteins in the blood.

Options: View larger image (or click on image) Download as PowerPoint
DEX prophylaxis in humans to travel to high elevation suppresses inflamm...
(A) Schematic reviewing the study design, in which 27 individuals from cohort-1 and 40 individuals from cohort-2 were flown from LA to HA. Individuals in the control group were not treated, whereas individuals in the DEX-P group were treated with 4 mg oral twice-daily DEX prophylaxis starting 1 day prior to travel, in an unblinded manner. Blood samples were drawn before (at LA) and after 3 days of HA exposure (at HA). Samples from both cohort-1 and cohort-2 were combined and analyzed together to increase statistical power. (B) Paired ECHO analysis showed higher RVSP 3 days after exposure to HA, and DEX prophylactic treatment showed a mild trend toward lowering RVSP in both cohorts. This clinical data of cohort-1 was previously published (47) and is reproduced here. HA exposure resulted in higher levels of (C) TSP-1 and (D) TGF-β1, while DEX prophylaxis blunted TSP-1 (C) and TGF-β1 (D) after 3 days at HA. DEX prophylaxis showed (E) no effect on blood CCL2 expression at HA day 3, but (F) significantly lowered CCL2 at HA day 1. There was a significant correlation of (G) RVSP with the cytokines TSP-1 and, mildly, with TGF-β1, as well as between (H) TSP-1 and TGF-β1 in the untreated participants. (I) DEX prophylaxis abrogated the (I) RVSP-cytokine and (J) TSP-1—TGF-β1 correlations. Paired t tests were performed within the individuals of the same group, while unpaired t tests were performed between control and DEX-p HA-exposed individuals. **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts